<DOC>
	<DOC>NCT01162850</DOC>
	<brief_summary>Primary Objective: To determine whether there is improvement in the melasma of participants taking oral Polypodium Leucotomos Secondary Objective: To determine whether oral Polypodium Leucotomos is well tolerated in study subjects with melasma. To determine whether treatment with Polypodium Leucotomos improves the health-related quality of life.</brief_summary>
	<brief_title>Oral Polypodium Leucotomos for Melasma</brief_title>
	<detailed_description>Polypodium Leucotomos is a fern, also known as Calaguala used by the natives of northern Honduras as a treatment against malignant tumors Used in Spain and Central America for the treatment of psoriasis, atopic dermatitis and repigmentation of vitiligo. Oral Polypodium Leucotomos is safe and effective in patients with melasma.</detailed_description>
	<mesh_term>Melanosis</mesh_term>
	<criteria>Healthy female subjects 1850 years of age. Female subjects with epidermal melasma. Female subjects of childbearing potential must have been willing to use an acceptable form of birth control for the duration of the study. Subjects with Fitzpatrick skin types II, III, &amp; IV Subjects enrolled in this trial had a 2 week washout period if on prior treatment for melasma. Pregnant or lactating Dermal Melasma Hormonal therapies less than or equal too 4 weeks prior to study Use of photosensitizing medications Simultaneous use of any form of treatment for melasma Subjects who were concurrently receiving light therapies Subjects who were unwilling to limit the amount of sun exposure Simultaneous ( or past 30 day) participation in a clinical research study.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Melasma</keyword>
</DOC>